Progress in the research on the treatment of secondary hyperparathyroidism

doi:10.3877/cma.j.issn.2095-3216.2022.05.007

Abstract

Abstract:

Secondary hyperparathyroidism (SHPT) is one of the most common complications in patients with advanced chronic kidney disease. High levels of parathyroid hormone in the patients can cause bone abnormalities and vascular calcification, and increase the incidence of cardiovascular events. At present, SHPT can be treated by drug therapy, interventional therapy, and traditional surgery, etc. This article reviewed the progress of research on treatment of SHPT so as to provide reference for clinical selection of therapies for SHPT.

Key words: Secondary hyperparathyroidism, Therapy, Surgery, Drug, Ultrasound

Wen Liu, Dan Luo, Xiaoyu Dai, Jianbo Xianyu, Yingjuan Yu, Chunlin Zhong, Dong Wang. Progress in the research on the treatment of secondary hyperparathyroidism[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 281-284.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.05.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I05/281

Figures/Tables 1

References 33

[32]	杨晓琦，陈安举，王田田，等. 继发性甲状旁腺功能亢进甲状旁腺全切除术的探讨[J]. 中华耳鼻咽喉头颈外科杂志，2020, 55(2): 98-103.
[33]	韩伟，吴云，张野. 右美托咪定对肾源性继发性甲状旁腺功能亢进症患者术后复发的影响[J]. 国际麻醉学与复苏杂志，2020, 41(12): 1146-1150.
[1]	Sun X, Zhang X, Zhang L, et al. Relationship between intraoperative measured parameters of parathyroid gland and pathological patterns in patients with secondary hyperparathyroidism [J]. Ann Transl Med, 2021, 9(2): 99.
[2]	Wen P, Xu L, Zhao S, et al. Risk factors for severe hypocalcemia in patients with secondary hyperparathyroidism after total parathyroidectomy [J]. Int J Endocrinol, 2021, 2021: 6613659.
[3]	Habas E Sr, Eledrisi M, Khan F, et al. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management [J]. Cureus, 2021, 13(7): e16388.
[4]	陈聪，陈祖辉，尹良红，等. 我国独立血液透析中心投资发展策略分析[J]. 临床医学工程，2021, 28(S1): 1-4.
[5]	Galassi A, Ciceri P, Fasulo E, et al. Management of secondary hyperparathyroidism in chronic kidney disease: a focus on the elderly [J]. Drugs Aging, 2019, 36(10): 885-895.
[6]	Wu Y, Liu Y, Huang T, et al. Application of nanocarbon negative imaging technology in surgery for secondary hyperparathyroidism [J]. Gland Surg, 2021, 10(8): 2455-2461.
[7]	Nakamura M, Tanaka K, Fujii T. Hyperparathyroidism caused by distant pulmonary lesions and parathyromatosis after ethanol injection/parathyroidectomy for secondary hyperparathyroidism [J]. Hemodial Int, 2017, 21(3): E45-E49.
[8]	梁辉，王文兵. 碳酸镧联合骨化三醇治疗维持性血液透析继发甲状旁腺功能亢进症的临床观察[J]. 检验医学与临床，2021, 18(10): 1485-1488.
[9]	陈孜瑾，陈晓农. 新型非含钙磷结合剂在慢性肾脏病-矿物质和骨异常患者中的临床应用[J]. 临床肾脏病杂志，2018, 18(9): 582-585.
[10]	代红梅，龚孝春，王瑞宁. 烟酰胺联合司维拉姆治疗血液透析高磷血症的临床研究[J]. 现代药物与临床，2018, 33(12): 3349-3353.
[11]	周加军，张凌. 活性维生素D及其类似物在CKD-MBD中的应用[J]．中国血液净化，2018, 17(6): 370-373.
[12]	李勇飞，杜庆生，李小妹. 大剂量骨化三醇冲击治疗终末期肾病并发继发性甲状旁腺功能亢进的临床效果观察[J]．吉林医学，2020, 41(5): 1141-1143.
[13]	刘威，刘昊虹，周兵，等. 骨化三醇和阿法骨化醇治疗血液透析患者继发性甲状旁腺功能亢进的疗效分析[J]. 吉林医学，2017, 38(5): 872-873.
[14]	Pun PH, Abdalla S, Block GA, et al. Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial [J]. Hemodial Int, 2016, 20(3): 421-431.
[15]	Subramanian R, Zhu X, Kerr SJ, et al. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide) [J]. Drug Metab Dispos, 2016, 44(8): 1319-1331.
[16]	Harada K, Fujioka A, Konno M, et al. Pharmacology of Parsabiv^® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients [J]. Eur J Pharmacol, 2019, 842: 139-145.
[17]	Block GA, Bushinsky DA, Cheng S, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial [J]. JAMA, 2017, 317(2): 156-164.
[18]	徐骏，王笑薇，刘旻，等. 碳酸镧联合西那卡塞、骨化三醇对血液透析伴继发性甲状旁腺功能亢进症的疗效[J]. 实用医学杂志，2021, 37(1): 82-86.
[19]	Chávez KV, Márquez-González H, Chavez-Tostado M. The usefulness of intraoperative PTH as a predictor for successful parathyroidectomy in secondary hyperparathyroidism [J]. Front Surg, 2021, 8: 696469.
[20]	Sharma J, Halkar R, Weber CJ. Imaging of parathyroid glands in end stage renal disease [J]. Semin Dial, 2017, 30(4): 369-372.
[21]	Qin X, Wang B, Li B, et al. Value of contrast-enhanced ultrasonography in radiofrequency ablation of secondary hyperparathyroidism [J]. Ren Fail, 2021, 43(1): 445-451.
[22]	吴静静，陆志强，刘凌晓. 射频消融术(RFA)治疗继发性甲状旁腺功能亢进(SHPT)的安全性及有效性分析[J]. 复旦学报(医学版), 2020, 47(2): 187-191.
[23]	吕珂，李建初，姜玉新. 超声造影临床应用进展[J]. 中国医学影像技术，2021, 37(12): 1761-1764.
[24]	方建强，赵维安，李庆，等. 超声引导下微波消融治疗继发性甲状旁腺功能亢进的短期疗效分析[J]. 中国超声医学杂志，2020, 36(5): 476-479.
[25]	于明安，姚力，彭丽丽，等. 超声引导下微波消融持续或复发性继发甲旁亢的临床研究[J]. 中国超声医学杂志，2017, 33(3) : 202 -205.
[26]	Zhuo L, Peng LL, Zhang YM, et al. US-guided microwave ablation of hyperplastic parathyroid glands: safety and efficacy in patients with end-stage renal disease-a pilot study [J]．Radiology, 2017, 282(2): 576-584.
[27]	Andrioli M, Riganti F, Pacella CM, et al. Long-term effectiveness of ultrasound-guided laser ablation of hyperfunctioning parathyroid adenomas: present and future perspectives [J]. AJR Am J Roentgenol, 2012, 199(5): 1164-1168.
[28]	Fei M, Xu D, Lai Y, et al. Comparison of different parathyroid autograft project after total parathyroidectomy in patients with secondary hyperparathyroidism [J]. Am J Otolaryngol, 2021, 42(6): 103085.
[29]	高恒元，许楠，罗勋鹏，等. 72例继发性甲状旁腺功能亢进行甲状旁腺次全切除术的治疗分析[J]. 中国现代普通外科进展，2017, 20(9): 684-686, 691.
[30]	Wang M, Chen B, Zou X, et al. A nomogram to predict hungry bone syndrome after parathyroidectomy in patients with secondary hyperparathyroidism [J]. J Surg Res, 2020, 255: 33-41.
[31]	Ge Y, Yang G, Wang N, et al. Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism [J]. Int Urol Nephrol, 2019, 51(8): 1443-1449.

Please choose a citation manager

Content to export